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A comparison of the clinical effectiveness and
costs of mental health nurse supplementary
prescribing and independent medical prescribing:
a post-test control group study
Ian J Norman1*†, Samantha Coster1†, Paul McCrone2†, Andrew Sibley3†, Cate Whittlesea4†
Abstract
Background: Supplementary prescribing for mental health nurses was first introduced in the UK in 2003. Since
then, a number of studies have reported stakeholders’ perceptions of the success of the initiative. However, there
has been little experimental research conducted into its effectiveness. This paper reports findings from the first
known study to compare the cost and clinical impact of mental health nurse supplementary prescribing to
independent medical prescribing.
Methods: A post-test control group experimental design was used to compare the treatment costs, clinical
outcomes and satisfaction of patients in receipt of mental health nurse supplementary prescribing with a matched
group of patients in receipt of independent prescribing from consultant psychiatrists. The sample comprised 45
patients in receipt of mental health nurse supplementary prescribing for a minimum of six months and a matched
group (by age, gender, diagnosis, and chronicity) of patients prescribed for by psychiatrists.
Results: There were no significant differences between patients in the nurse supplementary prescribers’ group and
the independent prescribers’ group in terms of medication adherence, health status, side effects, and satisfaction
with overall care. Total costs per patient for service use were £803 higher for the nurse prescribers’ group but this
difference was not significant (95% confidence interval -£1341 to £3020).
Conclusions: No significant differences were found between the health and social outcomes of patients in the
mental health nurse supplementary prescribers’ group, and those prescribed for by the independent medical
prescribers. The cost appraisal also showed that there was no significant difference in the costs of the two types of
prescribing, although the pattern of resources used differed between patients in the two prescriber groups. The
results suggest that mental health nurse supplementary prescribers can deliver similar health benefits to patients as
consultant psychiatrists without any significant difference in patients’ service utilisation costs.
Background
In 2001 suitably trained nurses were permitted to pre-
scribe from an extended formulary that included 120
different medicines within the areas of minor injury and
illness, palliative care, and health promotion [1]. How-
ever, it was not until 2003 that mental health nurses
were permitted to prescribe through the introduction of
supplementary prescribing [2]. Supplementary prescrib-
ing is described by the Department of Health (DH) [2]
as “a voluntary prescribing partnership between an inde-
pendent prescriber (a doctor or dentist) and a supple-
mentary prescriber (a pharmacist, nurse or midwife) to
implement an agreed patient-specific Clinical Manage-
ment Plan, with the patient’s agreement.” In order to be
registered as a supplementary prescriber, nurses attend
a 26-day university-based training programme, followed
by a period of supervised practice by an experienced
doctor.
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Since 2006, the extended Nurse Prescriber Formulary
has been discontinued and qualified independent nurse
prescribers can now prescribe all licensed medicines
from the British National Formulary including some
controlled drugs [3]. This latest development, was
described in a British Medical Journal (BMJ) editorial as
“one of the most far reaching extensions of prescribing
by nurses and pharmacists anywhere in the world” [4].
The British Medical Association responded to this new
policy of opening up the entire formulary to nurses with
dismay, expressing concerns about safety, and emphasis-
ing the importance of diagnostic training to prescribing.
Avery and Pringle [4] were more positive, noting that
training in diagnosis for non medical health profes-
sionals is becoming more widespread. They pointed to
findings from an influential study [5] which showed that
independent nurse prescribers prescribed for relatively
minor conditions and that medically trained assessors
had found that generally, they prescribed appropriately.
However, the BMJ editorial also pointed out that the
evidence base to support the current policy of non med-
ical prescribing was weak, and that it was “worrying that
the policy was launched by the Department of Health
before waiting for further evidence to accumulate,
including studies that it has only recently commis-
sioned.” This paper reports on findings from one of
these Department of Health (England) (DH)) commis-
sioned studies; a national evaluation of supplementary
prescribing by mental health nurses.
Much of the early literature on mental health nurse
supplementary prescribing in the UK consisted of expert
opinion, sometimes with the benefit of the authors hav-
ing visited mental health care settings in the USA, in
which nurses have exercised prescriptive authority for
over 20 years [6,7]. Within this anecdotal literature
there have been debates on: whether mental health
nurses have sufficient psychobiological knowledge to
undertake prescribing [8]; whether the legal protection
of nurses undertaking the role is adequate [9]; and
whether nurse prescribing has been introduced primarily
as a cost cutting measure [10], given the lower salaries
of nurses compared to doctors. Although there have
also been concerns regarding nurse prescribers’ aca-
demic knowledge and clinical experience [4], a recent
national survey by Courtenay et al. [11] suggested that
the qualifications and experience of many nurse prescri-
bers exceeds the training guidance stipulated by the
Nursing and Midwifery Council [12].
Nurse prescribers have been widely surveyed regarding
their experiences of their new role. On the whole, they
have been found to have positive views about the initia-
tive [13-16]. Although early surveys suggested that some
nurses were anxious about obtaining sufficient knowl-
edge and skills to carry out prescribing [17], practicing
non medical prescribers report gaining greater confi-
dence and knowledge of medicine management through
prescribing, as well as greater job satisfaction and
increased credibility with other professionals [16,18]. In
addition, despite some of the negative commentary
voiced by the medical profession [4], those studies
which have sought the views of NHS doctors on nurse
prescribing have found that they are broadly supportive
of the initiative if the nurse prescribers are well qualified
and experienced, and aware of their own limitations and
of the context in which they are prescribing [15,18]. Stu-
dies within mental health settings which have examined
psychiatrists’ views of nurse prescribing also suggest that
they are largely supportive of the nurse prescribing role
[15,19,20], with consultant psychiatrists appearing to be
less concerned about independent nurse prescribing
than their junior staff [19]. This is encouraging as the
relationship between the nurse supplementary prescriber
and consultant psychiatrist is likely to be key to the suc-
cess of non medical prescribing.
Perceived benefits of mental health nurse supplemen-
tary prescribing were that it would provide quicker and
more efficient patient access to medication, would
increase patient choice, and would make better use of
nurses’ skills and knowledge [21]. However, the effec-
tiveness of supplementary prescribing has been difficult
to ascertain. Recent case studies of nurse prescribers
(both supplementary and independent) working in non
mental health settings [22,23] suggest that staff perceive
that prescribing has helped them to provide more
streamlined packages of care, involve patients more in
prescribing decisions, be more responsive to patient
needs, and to work more holistically. Specifically Cour-
tenay et al [23] reported that nurse prescribers in der-
matology services felt able to spend longer in
consultations discussing medicines, and were able to
make prescribing decisions that were better tailored
towards their patients’ lives. There has been little com-
parable published research conducted within mental
health. However, mental health patients’ expectations of
prescribing have been found to be positive, although
tempered with uncertainty with regard to nurses’ pre-
scribing skills [24]. One study of patients’ views of sup-
plementary prescribing found that patients, on the
whole, valued the nurses’ holistic approach to medicine
management [25].
Nurse prescribing has also been identified as a poten-
tial way of improving medication management for
patients. Latter [26] suggests that prescribing medicines
provides a new opportunity to affect the way patients
take their medicines through maintaining good relation-
ships and providing appropriate information on medi-
cines. Certainly non compliance with medication in
mental health care is a substantial problem which has
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been strongly linked to patient rehospitalisation and
relapse [27] and non adherence rates for antipsychotics
have been estimated to be as high as 74% [28]. There
are to date no published studies which quantify the
impact of mental health nurse prescribing on concor-
dance. However, there is evidence gathered by Latter et
al. [26] that nurse prescribers are generally practicing
with due adherence to the main principles of
concordance.
The aim of the present study was to compare the out-
comes of patients prescribed for by a mental health
nurse supplementary prescriber with those in receipt of
independent medical prescribing. In view of the impor-
tance of taking medication appropriately, the primary
outcome utilised in the study was self-reported adher-
ence to medication. Secondary outcomes included clini-
cal and social outcomes, side effects and satisfaction. In
addition a cost consequences analysis was undertaken
which compared the service costs of patients in both
groups.
Methods
This study adopted a post-test control group experimen-
tal design in five mental health NHS trusts. The mental
health nurse prescribers’ group comprised patients who
had been in receipt of supplementary prescribing for at
least six months, and the comparison group comprised
a matched sample that had been in receipt of indepen-
dent medical prescribing for at least six months. Sample
size calculations showed that a sample of 60 patients in
each group would be sufficient to show that the mean
(adherence) score for patients managed by nurse pre-
scribers was equivalent to the mean score of patients
managed by independent medical prescribers within
(plus or minus) 0.47 with 80% power at the 5% level of
significance [29]. Due to practical difficulties involved in
recruiting patients within tight time constraints and
matching patients appropriately, the sample size was not
achieved. The effect size was recalculated on the basis of
the actual sample recruited which was 45 matched pairs
(n = 90) and was found to be 0.54, with 80% power at
the 5% level of significance.
Subjects were drawn from NHS trusts in which men-
tal health nurse supplementary prescribers provided a
service for a minimum of ten patients, with a primary
diagnosis of depression, anxiety or schizophrenia, for at
least six months. All patients were recruited to the
study by a member of the research team. Each of the
consenting patients in receipt of nurse supplementary
prescribing were matched on primary diagnosis, gender,
age group (within ten years) and length of time since
diagnosis as a measure of chronicity (within ten years)
to a patient whose medication had been managed by a
consultant psychiatrist working in the same local area of
practice. The only exclusion criterion applicable to
patients from both groups was being detained under the
Mental Health Act (1983) to ensure that consent was
informed. In the event of more than one possible con-
trol being available for a patient in the supplementary
prescribing group, a match from the independent medi-
cal prescriber’s caseload was drawn at random. The
study was approved by the Oxford REC A (Ref: 06/
Q1604/39) and was completed in 2007.
Outcome measures
Patients in the nurse prescriber and independent pre-
scriber groups were interviewed using a structured
interview (face to face or by telephone) comprising the
following scales:
• The five item Medication Adherence Report Scale
(MARS) [30] to measure medication adherence (primary
outcome);
• The 19 item Satisfaction with Information about
Medicines Scale (SIMS) [31] to measure satisfaction
with medication information;
• The Beck Depression Inventory for patients with a
primary diagnosis of depression [32] or the one item
quick rating of depressed mood in patients with anxiety
disorders [33] to measure depression in patients with
anxiety and schizophrenia;
• The Work and Social Adjustment Scale (WSAS) [34]
to assess social functioning and impairment;
• The one item Clinical Global Impression of
Improvement scale (CGI) [35] to assess the patient’s
perception of improvement in their health problem;
• The Short Assessment of Adverse Effects of Anti-
psychotic Medication Checklist [36]. The version used
in this study was adapted from the original checklist to
exclude those side effects which needed to be assessed
or observed by a clinician;
• The eight item Client Satisfaction Questionnaire
(CSQ-8) [37] to measure satisfaction with treatment
from the main care provider/organisation;
• To examine patients’ satisfaction specifically with
their prescriber, the following question was included:
“how satisfied are you with the person who prescribes
your medicines?” Responses were rated on a four point
scale from 1(very dissatisfied) to 4 (very satisfied).
Costs
A cost consequences analysis was undertaken in which
costs are reported alongside the multiple outcomes
which were investigated. The analysis was undertaken
from a health and social care perspective, which
included informal care from family/friends. The follow-
ing costs were included in the analysis:
1. The cost of the intervention (mental health nurse
supplementary prescribing)
This information was obtained from staff in the study
sites and included training costs (time off work to
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complete the prescribing training course, continuing
professional development, the cost of the supplementary
training course including travel expenses, book allowan-
ces, and time spent in supervision) and the costs of the
mental health nurse supplementary prescribing consulta-
tion (time spent preparing for a prescribing consulta-
tion, time taken to prescribe for a patient, and the
number of patients prescribed for.) We attempted to
include the costs of medication and tests ordered by the
prescribers, but the information provided by staff was
vague and so considered unreliable. It was therefore not
included within the final calculation. In addition,
although some data on consultation time with patients
were recorded by nurses, consultation costs were finally
calculated using data collected from patients as
described below. The median cost per patient was used
in the analyses, and sensitivity analyses were conducted
whereby the number of patients treated was changed.
2. Service costs of those patients prescribed to by nurses or
by doctors
Service utilization costs from patients in the nurse and
independent prescriber groups were collected using a
shortened version of the Client Services Receipt Inven-
tory (CSRI) [38]. The CSRI is one of the most com-
monly used measures of service costs. Its reliability and
validity has been established and it has the additional
advantage of enabling calculation of current standard
costs for services [38]. Information collected by the
CSRI included patients’ use of health (primary and sec-
ondary) care, social care inputs, and informal (unpaid)
care from family/friends as a result of the patients’
health problems. Use of these services was measured
retrospectively for the twelve months prior to interview.
Service costs for the period were calculated by combin-
ing service use data with unit costs for 2005/6 [39].
These unit costs are derived by defining annual staff
costs plus overheads (on-costs, training, capital, land,
etc) and an appropriate unit of activity (e.g. hour of
patient contact, inpatient day, etc). Informal care costs
were estimated by combining the weekly hours of care
with the unit cost of a homecare worker [39]. This was
based on the assumption that in the absence of the
carer it would be a homecare worker who would be
needed to provide this type of help.
All analyses were performed using SPSS for Windows
version 14. Paired t-tests were conducted to examine
differences in the key outcome measures (Medical
Adherence Report Scale, Satisfaction with Information
about Medicines Scale, Work and Social Adjustment
Scale, Beck Depression Inventory-II, One item Depres-
sion measure, the modified version of the Short Assess-
ment of Adverse Effects of Anti-psychotic Medication
Checklist, Clinical Global Impression of Improvement
Scale, the unvalidated satisfaction with prescriber item
and Client Satisfaction Questionnaire) between the two
groups (i.e. the independent medical prescriber and the
mental health nurse supplementary prescriber). Com-
pleted outcome scales which had one or more missing
items were eliminated from the analysis. As this strategy
resulted in very little data loss, it was not necessary to
consider the use of pro-rating data techniques. We did
not adjust for multiple testing as, with the exception of
adherence, we were not testing specific hypotheses
about the impact of either form of prescribing, and the
issue of multiple testing is less crucial in exploratory
analyses.
Cost differences for total service costs with and with-
out informal care were tested for statistical significance
using regression analysis with cost as the dependent
variable and the group identifier as the independent
variable. Cost data are usually skewed and therefore 95%
confidence intervals were constructed using
bootstrapping.
Results
Sample characteristics
Seventy two (87.8%) of the patients who were
approached for recruitment to the mental health nurse
supplementary prescribing group agreed to participate
in an interview. Eleven of these patients were inter-
viewed, but were subsequently dropped from the data
set because suitable matches from psychiatrists’ case-
loads could not be found before the project ended, or
their identified matches dropped out. Six patients
declined to be interviewed after providing consent. A
further eight patients were never interviewed because
suitable matches from psychiatrists’ caseloads could not
be found before the study ended. Two were unavailable
for interview after consent was taken due to re-hospita-
lisation. Fifty-five (79.7%) of the patients who were
approached for recruitment from the independent medi-
cal prescribers’ group consented to be interviewed; six
were matched with patients in the nurse supplementary
prescribers’ group who were subsequently not inter-
viewed, two declined to be interviewed after providing
consent, and two were also unavailable for interview.
Demographic characteristics for the entire sample of
90 participants (45 matched pairs) are shown in Table 1.
The mean age of the participants was 44.51 with a range
of 23 to 71 years, and 54.4% (57) of the sample were
men. Schizophrenia and depression were the largest
diagnostic groups, with the remainder of patients diag-
nosed with either bipolar disorder, schizoid affective dis-
order or anxiety.
The matching of subjects in the study was the closest
that was possible on available demographic and health
related criteria in an attempt to establish equivalence
between the intervention and comparison group. There
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were no significant differences between the matched
groups in terms of age or chronicity (Table 2). Ninety
one percent of patients in the nurses’ group (41/45) had
been in receipt of supplementary prescribing for a per-
iod of 12 months or longer, which exceeded the mini-
mum required prescribing period of six months.
Clinical outcomes and social functioning
Table 3 compares the scores of the two groups of
patients on the nine outcome measures. There were no
significant differences on the primary outcome of self
reported adherence to medication regimes, as assessed
by the Medical Adherence Report Scale. There were
also no significant differences found on any of the other
validated scales (the Satisfaction with Information about
Medicines Scale, the Work and Social Adjustment Scale,
the Beck Depression Inventory-II, the One item Depres-
sion measure, the modified version of the Short Assess-
ment of Adverse Effects of Anti-psychotic Medication
Checklist, the Clinical Global Impression of Improve-
ment Scale, and the Client Satisfaction Questionnaire).
The comparatively large confidence interval calculated
for the Beck Depression Inventory (BDI) measure, is a
reflection of a greater number of patients in the inde-
pendent prescribers’ group with high BDI scores.
There was a significant difference between the mean
scores of the two groups on the satisfaction item.
Patients in the nurse prescriber group reported a higher
level of satisfaction with their current prescriber than
those patients in the independent medical prescriber
group
Economic outcomes
Table 4 summarises information on service use and
costs. Notably patients in the independent medical pre-
scriber group had a greater mean frequency of contacts
with other therapists (e.g. art therapist, specialist chronic
fatigue therapist) than those in the nurse prescriber
group (10.1 mean contacts versus 35.0 mean contacts)
and a similar pattern emerged for psychiatric day care
(14.5 mean contacts versus 56.0 mean contacts).
Mean psychiatric inpatient user costs per patient were
substantially higher for the nurse prescriber group than
those in the medical prescriber group (£2049 versus
£863). This reflects the fact that twice as many patients
in the nurse prescriber group (n = 9, 20% of the total
nurse prescriber sample) had an inpatient stay during
the previous 12 months compared to those patients in
the independent medical prescriber group (n = 4, 9% of
the total medical prescribers’ sample). Although this
amounted to only five more patients in the nurse pre-
scriber group who experienced psychiatric inpatient
stays, the costs of these were so great compared to all
other costs that they led to a substantial difference in
costs between the two forms of prescribing.
The total annual cost per patient, excluding informal
care, was £803 higher for the mental health nurse sup-
plementary prescribers’ patients, but this difference was
not significant (95% CI, -£1341 to £3020). The costs
including informal care were £1713 higher for the nurse
prescriber group but again this was not significantly dif-
ferent (95% CI, -£3950 to £6699).
Figure 1 shows the impact on total service costs
(excluding informal care) as the caseload (or number of
patients prescribed for by the nurse) increases as a func-
tion of time. The effect of the increased number of
patients reduces the unit cost of the intervention, but
the figure shows that this has a modest effect on total
costs. Even if numbers increased by 200% the costs
would remain above those for the independent medical
prescriber group, although the difference would not be
significant.
Cost of implementing supplementary nurse prescribing
An additional cost to be considered by trusts which
decide to establish a nurse supplementary prescribing
service is the cost of nurse prescriber training, which we
calculated per patient at £497. Other costs would
include those for professional updating and supervision
by doctors. Although such data were collected during
the course of the study, no attempt to calculate an aver-
age for these additional costs was made.
Discussion
The study demonstrates that there were no significant
differences in self reported adherence to medication
between patients who had been prescribed for by a
Table 1 Sample characteristics (n = 90)
Characteristics Mean (SD)
Age (M) (SD) 44.51 (10.84)
Gender 54.4% Male
45.6% Female
Chronicity (years since diagnosis)
Range: <1-15
8.69 years (3.18)
Diagnosis
Depression 30 (33.3%)
Bipolar 24 (26.7%)
Schizophrenia 32 (35.6%)
Schizoid affective 2 (2.2%)
Anxiety 2 (2.2%)
Table 2 Differences between matched groups on
matching characteristics
Sample N Nurse
prescriber
Medical
prescriber
Mean (SD) Mean (SD) Sig (p)
Age 45 44.10 (11.13) 45.11 (10.58) 0.732
Chronicity 45 9.16 (3.59) 8.20 (2.66) 0.101
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nurse prescriber for a period of at least six months and
those prescribed for by an independent medical prescri-
ber. Patients in the nurse supplementary prescriber
group did report significantly higher satisfaction with
their prescriber on an unvalidated measure, but as this
was an exploratory analysis with improvement in satis-
faction not being an a priori hypothesis, and given the
number of tests conducted, it may have been a chance
finding. There was no difference found on the validated
satisfaction measure, the Client Satisfaction Question-
naire. However as this scale was developed to assess
satisfaction with all aspects of healthcare, it is therefore
likely that service users considered the care received
from a range of health professionals in addition to their
prescriber when rating this scale. Further research is
needed to develop self-report measures which can reli-
ably quantify mental health patients’ satisfaction with
supplementary prescribing.
The economic evaluation of mental health nurse sup-
plementary prescribing is particularly important given
the finding of no significant difference between adher-
ence, and the clinical and social outcomes of patients in
receipt of supplementary prescribing and independent
medical prescribing. If both forms of prescribing are
equivalent, then a key question is which one is less
expensive? Our cost appraisal shows no significant
difference in the costs of the two types of prescribing.
However, the pattern of resources used differed between
patients in the two prescriber groups. Service users in
the independent medical prescribers’ group had a
greater mean contact with other therapists (e.g. art
therapist, specialist chronic fatigue therapist) and
reported more use of psychiatric day care than those in
the nurses’ group although differences in these costs
were not significant. Patients in the nurse prescribers’
group were more likely to have been admitted as psy-
chiatric inpatients during the previous 12 months, than
those patients in the independent medical prescribers’
group. However, it is not possible to ascertain the rea-
son for this difference in admission days. Given that
there were only five more patients (out of a total sample
of 90) requiring inpatient treatment in the mental health
nurses’ group, this might be a chance finding. Or it
might be that nurses are more inclined than doctors to
refer patients whose behaviour gives rise to concern to
inpatient care facilities; this may reflect their lesser
experience and possibly their lower level of confidence
in their skills of risk assessment than doctors, whose
patients appeared to utilise day services more often.
The finding that the nurses’ group had more inpatient
stays is particularly interesting, given the fact that the
independent prescriber group had a higher depression
Table 3 Comparison of health and social outcomes between the independent prescriber and nurse supplementary
prescriber groups.
Nurse prescriber Medical prescriber 95% CI of mean difference
N Mean (SD) Mean (SD)
SIMS overall score (0-17 : 17
= high satisfaction)
88 12.7 (4.22) 12.13 (4.33) -1.45 to 2.40
MARS (5-25: 5 = high
adherence
88 21.25 (4.09) 21.90 (2.68) -2.25 to 0.94
WSAS: Work & Social
Adjustment Scale
(0-40 : 40 = severe)
89 17.18 (17.05) 16.72 (10.08) -4.17 to 4.62
Clinical Global Impression
Scale (1-7 : 7 = severe)
88 3.56 (1.47) 3.22 (1.49) -0.24 to 0.91
BDI-II Mean Score
(Depression/Bipolar only
patients)
(0-63 : 63 = severe
depression)
46 17.95 (17.06) 20.69 (14.08) -9.72 to 5.42
One item depression scale
(Anxiety, Schizophrenia
patients only) (1-8 : 8 =
severe)
36 3.25 (1.98) 3.11 (0.83) -0.67 to 1.04
CSQ-8 (8-32 : 32 = high
satisfaction)
89 21.43 (5.35) 25.17(4.06) -1.63 to 2.18
Side effects score (0-14; 14 =
high prevalence of side
effects)
90 4.06 (2.57) 4.44 (2.71) -1.46 to 0.70
Satisfaction with prescriber
(1-4 : 4 = high satisfaction)
90 3.42 (0.87) 3.04 (0.79) 0.03 to 0.72
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score (although not significantly) than the mental health
nurses’ group. The independent prescribers’ group may
have been more severely ill, because more severe or
unstable cases might have been retained by the doctors,
whilst the more chronic and stable cases might have
been transferred to mental health nurses. However, this
is speculation as we have no firm evidence from this
study that illness severity was a criterion which deter-
mined case allocation to the nurses.
Strengths and limitations
This is the only known national evaluation of mental
health nurse supplementary prescribing in the UK, and
the first to adopt an experimental research design to
compare outcomes and costs for patients managed by
nurse supplementary prescribing and independent medi-
cal prescribing. Thus, the study represents an advance
on expert opinion papers, and adds to previous research
on the views of staff [13,14] and patients [24,25] towards
nurse prescribing as a policy initiative.
The results of this study are encouraging for the
future of supplementary prescribing since it suggests
that prescribing by mental health nurses may be as
effective as the ‘gold standard’, that is prescribing by
independent medical prescribers. However, it would be
premature to draw any overall conclusions on the basis
of this single study. Whilst subjects in both groups were
matched on several characteristics, it was not possible to
match them at baseline (on commencement of nurse
supplementary prescribing) on diagnostic specific, gen-
eric health or social care outcomes. This raises the pos-
sibility that one or other group of subjects was more
seriously ill at baseline and so made more progress than
the other over the prescribing period. Even if health out-
come data had been available at baseline, drawing con-
clusions about causality would remain contentious in
the absence of randomisation of subjects to the care of
either the mental health nurse or the independent medi-
cal prescriber.
Patients’ health outcomes in this study were assessed
using self-report measures. Assessing adherence using
clinicians’ reports, pill counts or biological measures, are
time consuming and are not always accurate [40].
Patient self-report methods also have disadvantages, and
it has been suggested that self-report measures overesti-
mate adherence rates [41]. However, given that no
method is ideal, validated self-report scales are generally
Table 4 Service use and costs per patient over 12 months of mental health nurse supplementary prescribing
compared to independent medical prescribing
Nurse supplementary prescriber group Independent medical prescriber group
Service N (%) using
Service
Mean (SD)
Contacts1
Mean (SD)
Cost (£)2
N (%) using service Mean (SD)
Contacts1
Mean (SD
Cost (£)2
Intervention 45 (100) - 497 (0) 0 (0) - 0 (0)
Medical outpatient/
Daycare
9 (20) 5.1 (5.1) 99 (297) 4 (9) 3.8 (3.8) 33 (143)
Psychiatric day care 10 (22) 14.5 (27.1) 76 (304) 8 (18) 56.0 (51.8) 312 (1154)
Non-psychiatric nurse 21 (46) 6.6 (8.3) 89 (287) 12 (27) 7.5 (13.3) 113 (612)
Other therapist 8 (17) 10.1 (11.4) 79 (324) 6 (14) 35.0 (40.3) 340 (1274)
Psychiatrist 33 (72) 8.9 (9.6) 612 (1012) 37 (84) 13.9 (9.2) 1032 (972)
OT/vocational worker 4 (9) 2.8 (2.4) 6 (25) 1 (2) 5.0 (-) 5 (30)
Social care 6 (13) 11.6 (8.8) 106 (379) 8 (18) 18.1 (8.3) 181 (613)
Psychiatric inpatient3 9 (20) 52.1 (44.1) 2049 (5622) 4 (9) 47.3 (49.8) 863 (3824)
Medical inpatient3 5 (11) 3.0 (0.7) 79 (235) 1 (2) 7.0 (-) 39 (256)
GP 33 (72) 8.3 (11.4) 159 (314) 40 (91) 5.0 (4.2) 140 (163)
Psychologist 3 (7) 13.8 (1.1) 59 (227) 3 (7) 15.0 (8.9) 68 (282)
CMHN 35 (76) 22.1 (16.5) 603 (600) 16 (36) 36.4 (20.7) 594 (1008)
A&E 6 (13) 1.2 (0.4) 13 (37) 2 (5) 1.5 (0.7) 6 (29)
Informal care 17 (37) 1196 (994) 6188 (11645) 16 (36) 1037 (1368) 5278 (13336)
Total excluding
informal care
4526 (5996) 3723 (4391)
(95% CI, £-1341 to
£3020)
Total including
informal care
10714 (13257) 9001 (14465)
(95% CI, £-3950 to
£6699)
1 Contacts for those using services only
2 Costs in 2005/6 £s and for whole sample
3 Contacts = number of days
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considered to be a cost-effective and time-efficient way
of assessing adherence [42]. In addition, any over esti-
mation of adherence by patients was equally likely to
occur in both the nurses’ and psychiatrists’ groups, and
so was unlikely to confound the results of this study.
In this evaluation we sought to calculate incremental
costs, that is, the additional costs that would be incurred
by NHS trusts on implementation of mental health
nurse supplementary prescribing. It was beyond the
scope of the evaluation to consider issues such as the
economic effects of longer term changes in skill mix
within trusts, which might arise if mental health nurse
supplementary prescribing was adopted widely. Investing
in professional skills is like any other investment, in that
the returns come as a flow of benefits over time. In
addition skills require maintenance and continuing
development, and much will depend also on how long
the nurse prescribers, once trained, continue to deliver a
prescribing service for patients.
Conclusions
Whether supplementary prescribing or independent pre-
scribing is a desirable development must depend ulti-
mately on its benefit for patients and, more specifically,
whether it is as cost effective as the current standard
system of prescribing by independent medical practi-
tioners. The most important consideration when
planning the future of mental health nurse supplemen-
tary prescribing is the experience and wellbeing of
patients. This evaluation suggests that the effect on
patients of transferring from an independent medical
prescriber to a mental health nurse prescriber may be
negligible, which is encouraging for the future of mental
health nurse supplementary prescribing.
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